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Although it is established that the receptor activity modifying proteins (RAMPs) can interact with a number of GPCRs, little is
known about the consequences of these interactions. Here the interaction of RAMPs with the glucagon-like peptide 1 receptor
(GLP-1 receptor), the human vasoactive intestinal polypeptide/pituitary AC-activating peptide 2 receptor (VPAC2) and the type
1 corticotrophin releasing factor receptor (CRF1) has been examined.
EXPERIMENTAL APPROACH
GPCRs were co-transfected with RAMPs in HEK 293S and CHO-K1 cells. Cell surface expression of RAMPs and GPCRs was
examined by ELISA. Where there was evidence for interactions, agonist-stimulated cAMP production, Ca2+ mobilization and
GTPgS binding to Gs, Gi, G12 and Gq were examined. The ability of CRF to stimulate adrenal corticotrophic hormone release in
Ramp2+/– mice was assessed.
KEY RESULTS
The GLP-1 receptor failed to enhance the cell surface expression of any RAMP. VPAC2 enhanced the cell surface expression of
all three RAMPs. CRF1 enhanced the cell surface expression of RAMP2; the cell surface expression of CRF1 was also increased.
There was no effect on agonist-stimulated cAMP production. However, there was enhanced G-protein coupling in a receptor
and agonist-dependent manner. The CRF1 : RAMP2 complex resulted in enhanced elevation of intracellular calcium to CRF
and urocortin 1 but not sauvagine. In Ramp2+/– mice, there was a loss of responsiveness to CRF.
CONCLUSIONS AND IMPLICATIONS
The VPAC2 and CRF1 receptors interact with RAMPs. This modulates G-protein coupling in an agonist-specific manner. For
CRF1, coupling to RAMP2 may be of physiological significance.
Abbreviations
ACTH, adrenal corticotrophic hormone; CGRP, calcitonin gene-related peptide; CLR, calcitonin receptor-like receptor;
CTR, calcitonin receptor; GLP-1, glucagon-like peptide 1; HA, haemagglutinin; RAMP, receptor activity modifying
proteins; PACAP, pituitary AC-activating peptide; PHM-27, peptide histidine methionine-27; VIP, vasoactive intestinal
polypeptide; WT, wild-type
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Introduction
Receptor activity-modifying proteins (RAMPs) consist, in
mammals, of three single-pass transmembrane proteins, first
identified as essential components of calcitonin gene-related
peptide (CGRP) and adrenomedullin receptors (McLatchie
et al., 1998). They associate in the endoplasmic reticulum
with a GPCR known as calcitonin receptor-like receptor
(CLR). The RAMPs and CLR by themselves have poor abilities
to reach the cell surface and cannot bind any known endog-
enous ligand. However, the complexes are translocated to the
cell surface where they respond to CGRP, adrenomedullin
and adrenomedullin 2 via CGRP, AM1 and AM2 receptors
(Poyner et al., 2002; Wootten et al., 2010; Hong et al., 2011).
The trafficking of adrenomedullin receptors is also influenced
by the RAMPs (Bomberger et al., 2005).
RAMPs have subsequently been shown to interact with a
wider range of GPCRs. The best characterized of these inter-
actions is with the calcitonin receptor (CTR), where the
RAMPs do not alter receptor cell surface expression but
instead change ligand binding and G-protein coupling to give
amylin receptors (Hay et al., 2006; Morfis et al., 2008). RAMPs
1 and 3 are needed for cell surface expression of the calcium
sensing receptor, a glutamate-like/family C GPCR (Bouschet
et al., 2005). However, most interest has focussed on secretin-
like/family B GPCRs. By monitoring the ability of GPCRs to
increase the cell surface expression of RAMPs, it has been
shown that the vasoactive intestinal polypeptide (VIP)/
pituitary AC-activating peptide 1 receptor (VPAC1) could
interact with all three RAMPs, the parathyroid hormone
PTH1 receptor could interact with RAMP2, the parathyroid
hormone PTH2 receptor could interact with RAMP3 and the
glucagon receptor could interact with RAMP2. No evidence
was found for interactions between RAMPs and the VPAC2 or
either the GLP-1 or GLP-2 receptors (Christopoulos et al.,
2003). Only in the case of the VPAC1 was there any charac-
terization of the effects of RAMP association. The complex
with RAMP2 had normal expression and pharmacology for
activation of AC, but the maximum stimulation of phosph-
oinositide turnover in response to VIP was increased (Chris-
topoulos et al., 2003). It would seem unlikely that there is no
consequence of RAMP association with these different recep-
tors. Indeed, recent studies of Ramp2+/– knockdown mice has
shown there was a wide range of phenotypic changes that go
far beyond what would be expected for effects mediated by
peptides acting through CLR and CTR/RAMP complexes
(Kadmiel et al., 2011).
In this study, the ability of three family B GPCRs, the type
1 corticotrophin releasing factor receptor (CRF1), the GLP-1
receptor and the VPAC2 receptor to interact with all three
RAMPs have been examined in HEK 293S and CHO-K1 cells.
These receptors are of potential therapeutic interest. In evo-
lutionary terms, the CRF1 is the closest family B GPCR to the
CTR and CLR (Fredriksson et al., 2003), but its ability to
interact with RAMPs has not previously been investigated.
The VPAC2 and GLP-1 receptor are on the other two main
branches that make up secretin-like/family B GPCR family.
The results show that the VPAC2 can interact with all three
RAMPs, and the CRF1 can interact with RAMP2. These inter-
actions differentially modulate G-protein coupling; in the
case of the CRF1, it is shown that this alters the pattern of
calcium signalling and furthermore, in Ramp2+/– mice, the
physiological effects of CRF on adrenal corticotrophic
hormone (ACTH) release are reduced.
Methods
Materials
Peptides were from Bachem (St. Helens, UK). Unless other-
wise specified, chemicals were from Sigma or Fisher (Lough-
borough, UK). Cell culture reagents were from Gibco BRL
(Paisley, Renfrewshire, UK) or Sigma. Monoclonal anti-HA,
mouse clone HA-7, monoclonal mouse anti-FLAG, clone M2
and monoclonal goat anti-mouse antibody containing a con-
jugated HRP were purchased from Sigma. G-protein antibod-
ies (Gs, Gq/11, G12/13, Gi/o/t/z) were from Santa Cruz (Santa Cruz,
CA).
Expression constructs
Plasmid DNA was extracted from the cultures using a Wizard-
Prep DNA extraction kit according to the manufacturer’s
instructions (Promega, Southampton, UK). The plasmid DNA
was eluted in 100 mL sterile distilled water and stored at
-20°C. For all receptors, a pcDNA3.1– template vector was
produced containing a T8 signal peptide and a HA-Tag
(cloned in using NotI and EcoRI). The mature protein
sequence for each receptor was then cloned in using EcoRI
and HindIII. The EcoRI site between the tag, and the receptor
sequence was removed using Quikchange. The RAMPs were
modified with a FLAG tag inserted just before residue 24
(RAMP1), 42 (RAMP2) and 25 (RAMP3). A pcDNA3.1+ tem-
plate vector was produced containing a CD33 signal peptide
and a FLAG-Tag (cloned in using HindIII and EcoRI). The
mature protein sequence for each RAMP was then cloned in
using EcoRI and XhoI. The EcoRI site between the tag, and the
RAMP sequence was removed using site mutagenesis with a
Quikchange kit (Stratagene, Leicester, UK). The untagged
constructs were in pcDNA3.1– and were either gifts from
AstraZeneca (receptors) or Dr Steve Foord, GSK-Wellcome
(RAMPs). The CRF1 receptor was isoform 1, which includes
residues 147–176.
Cell culture and transfection
Cells were cultured in DMEM supplemented with 10% (v/v)
FBS and 5 % (v/v) penicillin/streptomycin in a humidified
95% air/5% CO2 atmosphere. For transfection, the cells were
plated onto either 12- and 48-well plates or 100 mm dishes.
Cells were transfected using a mixture (per 1 mg DNA) of 6 mL
10 mM polyethyleneimine and 45 mL 5% glucose solution
incubated for 30 min at room temperature and added to an
appropriate final volume of full media. Twelve- and 48-well
plates were treated with 1 mg DNA per well, and 100 mm
dishes were treated with 10 mg DNA per dish. The ratio of
RAMP to receptor cDNA was 1:1 unless otherwise stated;
where receptor or RAMP alone was transfected, the balance to
1 or 10 mg was made up with empty pcDNA3.1– vector. Char-
acterization of expressed receptors was performed 48–72 h
after transfection.
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Real-time quantitative PCR
Cells from confluent flasks were washed briefly with 1 mL
cold PBS, detached with versene and pelleted by spinning at
350¥ g for 5 min. Total cellular RNA was isolated using the
RNeasy kit and Qiashredder columns from Qiagen (Crawley,
UK) following the manufacturer’s recommendations. RNA
isolated 48 h post transfection from HEK-293S cells and
CHO-K1 cells transfected with cDNAs for human RAMP1,
RAMP2 and RAMP3 were used as positive controls. RNA
concentration was calculated based on the absorbance at
260 nm. cDNA was generated from 5 mg of total RNA by using
the Promega Reverse Transcription System. Quantification of
RAMP1, RAMP2 and RAMP3 expression was performed by a
real-time PCR Roche lightcycler (Burgess Hill, UK) and the
SYBER green I PCR kit for the lightcycler following the manu-
facturer’s protocol. RAMP expression was standardized to the
expression of the housekeeping gene GADPH.
Membrane preparation
Cells from 100 mm dishes were washed briefly with 1 mL
cold PBS. They were detached with versene and pelleted by
spinning at 350¥ g for 5 min at room temperature. The pellet
was washed in ice-cold homogenization buffer (100 mM
NaCl, 10 mM MgCl2, 50 mM HEPES, pH 7.4), homogenized
and then spun at 1700¥ g at 4°C for 10 min to pellet the
nuclei. The supernatant was then respun at 40 000¥ g at 4°C
for 90 min. The pellet was resuspended in homogenization
buffer and stored at -80°C.
GTPgS binding
The binding reaction was set up on ice in 1.5 mL tubes in a
final volume of 500 mL of assay buffer (10 mM NaCl, 10 mM
MgCl2, 0.2% BSA, 20 mM HEPES, pH 7.4) containing 150 mg
membrane, 0.01% saponin and either 1 mM (for Gs) or 0.1 mM
GDP (G12/13, Gq/11 and Gi/o/t/z). After a 60 min preincubation at
30°C, 200 pM [35S]-GTPgS was added and incubated for a
further 30 min at 30°C. The reaction was terminated by
adding 1 mL ice-cold assay buffer and centrifuged in a refrig-
erated microfuge at full speed for 6 min. The pellet was
washed with 100 mL of ice-cold solubilization buffer (assay
buffer with 1.25% NP40) and left on ice for 30 min to solu-
bilise; 2 mg of the appropriate anti-Ga subunit antibody was
added and incubated overnight at 4°C; 50 mL of 30% slurry of
protein-A (pre-equilibrated in assay buffer) was added and left
at 4°C for 90 min. After washing twice with 500 mL of cold 1¥
solubilization solution, the pellet was resuspended with
100 mL of solubilization buffer supplemented with 0.2% SDS
and measured by scintillation counting.
Assay of cAMP production
Growth medium was removed from the cells and replaced
with DMEM containing 500 mM isobutyl methyl xanthine for
30 min. Peptides in the range 10 pM to 1 mM were added for
a further 15 min. Ice-cold ethanol (95–100% v/v) was used to
extract cAMP, which was subsequently measured by radio-
receptor assay as previously described (Poyner et al., 1992).
Data were normalized with respect to addition of 10 mM
forskolin.
Measurements of intracellular Ca2+
Transfected cells were seeded in growth medium at 5 ¥ 104
cells per well in black, clear-bottomed, 96-well plates and
incubated overnight. Cells were washed with PBS, loaded
with 100 mL per well of loading buffer (1X HBSS/20 mM
HEPES/2 mM CaCl2, pH 7.4) containing 5 mM probenecid
and incubated at 37°C for 1 h. Fluorescence was determined
using a FlexStation (Molecular Devices, Sunnyvale, CA)
immediately after peptide ligand addition with excitation
wavelength 485 nm and emission wavelength to 520 nm.
Peak magnitude was determined using five-point smoothing,
followed by correction against basal fluorescence.
Analysis of cell-surface expression by ELISA
Cells in 12-well plates were transiently transfected with recep-
tors and RAMPs as appropriate. Details were as described
previously (Conner et al., 2005). The cells were treated with
250 mL of primary antibody (mouse, anti-HA antibody HA-7
or mouse anti-FLAG M2 [Sigma] diluted 1:2000 in PBS with
5% BSA) for 1 h.
Measurement of ACTH
Ramp2+/– mice on an isogenic 129S6/SvEv genetic background
have been previously described ((Dackor et al., 2007; Kadmiel
et al., 2011). Ramp2+/– (n = 6) and wild-type control (n = 8)
mice were injected i.p. with CRF, (40 mg kg-1, #H-2435,
Bachem, Torrance, CA.) to stimulate release of ACTH. Blood
samples were collected via sub-mandibular bleed after 2 h. An
ultra-sensitive chemiluminescence ELISA kit (#MBS580004,
MyBioSource; San Diego, CA) was used according to the
manufacturer’s protocol to measure plasma levels of ACTH.
Briefly, plasma samples were incubated a goat polyclonal
antibody and a mouse monoclonal antibody to ACTH. One
antibody is biotinylated and binds only the C-terminal of
ACTH 34–39. The other antibody is labelled with HRP and
binds only the mid-region and N-terminal of ACTH 1–24. The
samples were then incubated with an enzyme-labelled anti-
body and a biotin coupled antibody in a streptavidin-coated
microplate and analysed by addition of a luminal substrate.
Concentrations of ACTH present in the controls and samples
are determined from a standard curve and plotted as plasma
ACTH (pg mL-1). Experimental animals were 6–8 months of
age, and control animals were wild-type, age- and gender-
matched littermates. Animals were fed ad libitum and housed
in standard 12 h/12 h light/dark cycle. All studies involving
animals are reported in accordance with the ARRIVE guide-
lines for reporting experiments involving animals (Kilkenny
et al., 2010; McGrath et al., 2010). All experiments were
approved by the Institutional Animal Care and Use Commit-
tee of the University of North Carolina at Chapel Hill.
Data analysis
Curve fitting was done with PRISM GraphPad 4 (GraphPad
Software Inc., San Diego, CA). The data from each
concentration–response curve were fitted to a sigmoidal
concentration–response curve to obtain the maximum
response and –logEC50 (pEC50). pEC50, basal and maximal
responses were compared by paired Student’s t-test or by
one-way ANOVA followed by Dunnett’s test when multiple
comparisons were made. Data from ELISAs were compared by
the Mann–Whitney test. n-values refer to the number of
independent experiments.
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Results
Characterization of cell lines and receptors
As the effects of RAMPs are heavily influenced by cell line
background (Tilakaratne et al., 2000; Udawela et al., 2006a),
HEK 293S and CHO-K1 cells were both used in this study.
They were first examined for expression of endogenous
RAMPs by RT-PCR. The highest endogenous expression was
that for RAMP2 in HEK 293S cells (5.1  1.1% of GAPDH
expression); in all other cases, endogenous RAMP expression
was not more than 2.25% of GAPDH. As an added check,
both cell lines were transfected with CLR alone and chal-
lenged with either CGRP or adrenomedullin at concentra-
tions from 0.01 to 1000 nM. In no case was there any
detectable increase in cAMP. Thus, there was insufficient
endogenous RAMP expression to generate CGRP, AM1 or AM2
receptors (Supporting Information Figures S1 and S2).
The pharmacology of N-terminal, HA-tagged CRF1, CTR,
GLP-1 receptor and VPAC2 were compared with the untagged
receptors, by measuring the ability of CRF, calcitonin, GLP-
1(7–36)amide (GLP1) or VIP to stimulate cAMP production in
cells transfected with their cognate receptor. In no case was
there any difference in pEC50, maximal or basal responses
between the tagged and untagged receptors (Supporting
Information Figure S3). Similarly, the properties of N-
terminal FLAG-tagged RAMP1, 2 and 3 were compared with
untagged RAMPs by co-transfecting with CLR and measuring
the ability of either CGRP or adrenomedullin to stimulate
cAMP at the resulting CGRP or adrenomedullin receptors.
Again, there was no difference between the responses of
the tagged and untagged RAMPs (Supporting Information
Figure S4).
Cell surface expression of
receptor–RAMP complexes
To investigate potential interactions between receptors and
RAMPs, the ability of interacting receptors to increase cell
surface RAMP expression was examined (Table 1) (Chris-
topoulos et al., 2003). As expected, cell surface expression of
RAMPs transfected on their own was poor in both HEK 293S
and CHO-K1 cells, but it was enhanced by co-transfection of
the CTR. Co-transfection with GLP-1 receptor had no effect
on RAMP expression. By contrast, VPAC2 co-transfection sig-
nificantly enhanced the expression of all three RAMPs in
both cell lines; the largest change was seen for RAMP1
whereas the increase with RAMP3 was much smaller.
Co-transfection with CRF1 enhanced cell surface expression
of RAMP2 alone. In all cases, the enhancement of RAMP cell
surface expression was greatest with the HEK 293S cells.
With both CLR and the calcium sensing receptor, there is
a reciprocal interaction, whereby RAMPs also enhance the
cell surface expression of the receptor (McLatchie et al., 1998;
Bouschet et al., 2005). Accordingly, the ability of RAMPs to
traffic the receptors to the cell surface was also examined
(Table 2). Only RAMP2 had any effects, increasing the deliv-
ery of CRF1. Consistent with the data on RAMP expression,
the effect was larger in HEK 293S cells compared with
CHO-K1 cells.
Effects on receptor pharmacology
The effects of RAMP expression on the pharmacology of the
VPAC2 and CRF1 were investigated by examining the ability of
a range of agonists to stimulate cAMP production. For the
VPAC2, the receptor was co-expressed with all three RAMPs in
HEK 293S and CHO-K1 cells and challenged with VIP, BAY
55-9837, PACAP-27 and PHM-27 (Figure 1). These are all ago-
nists at VIP/PACAP receptors with good potency against
VPAC2 receptors; BAY 55-9837 is selective for this subtype
(Tsutsumi et al., 2002). In no case was there any difference in
the response of the receptors to the agonists. HEK 293S cells
appeared to express an endogenous PAC1 receptor, as the
untransfected cells showed a good response to PACAP-27
(Figure 1B, pEC50 8.74  0.09, Emax 97  2%) and PHM-27
(Figure 1D; pEC50 8.60  0.12, Emax 62  2%). However, for
VIP and BAY 55-9837 (Figure 1A, C) in these cells as well as
for all four agonists in the CHO-K1 cells (Figure 1E–H), there
was little response in untransfected cells so the lack of effect
of the RAMPs was clear. There was a modest increases in basal
cAMP production for the VPAC1 receptor expressed with
RAMP1 (23.5  2.5%) and a slight decrease with RAMP3 (-9.0
 3.5%) compared with VPAC1 alone (8.0  2.1%) (Figure 1B,
P < 0.01 and 0.05, respectively, Dunnett’s test following one-
way ANOVA). For the CRF1, the receptor was co-expressed with
RAMP2 in HEK 293S cells and challenged with CRF, urocortin
1, and sauvagine (all agonists at the CRF1 receptor) (Dautzen-
berg et al., 2001). In addition, for CRF challenge, the receptor
was also expressed with RAMP1 and RAMP3 (Figure 2). In no
Table 1
Cell surface expression of RAMPs in the presence or absence of receptors
RAMP
HEK 293S CHO-K1
CTR VPAC2 GLP-1R CRF1 pcDNA3 CTR VPAC2 GLP-1R CRF1 pcDNA3
1 100 69  5* 6  1 2  2 3  2 100 45  4* 2  2 5  2 2  2
2 100 62  6* 24  3 57  4* 22  6 100 36  7* 17  3 39  4* 15  4
3 100 49  5* 30  8 27  5 36  4 100 32  5* 13  6 22  6 19  3
RAMPs were detected by cell surface ELISA of their FLAG tag. Expression was normalized (100%) to that seen when each RAMP was
co-expressed with CTR. To determine receptor-independent expression, cells were co-transfected with the appropriate RAMP and empty
vector (pcDNA3). Values are means  SEM, n > 3.
*Expression significantly different from pcDNA3, P < 0.05, Mann–Whitney.
BJPRAMP interactions with VPAC2 and CRF1 receptors
British Journal of Pharmacology (2013) 168 822–834 825
case was there any difference in the response of the receptors
to the agonists. The experiments were also repeated in
CHO-K1 cells with identical results (Supporting Information
Figures S5 and S6).
GTPgS binding
To investigate if the RAMPs could modulate G-protein
coupling, agonist-stimulated GTPgS binding to different
G-proteins was investigated. For the VPAC2, there was no
effect on VIP-stimulated GTPgS binding to Gs (Figure 3).
However, RAMP1 and RAMP2 significantly increased basal
coupling to Gi/o/t/z in both cell lines (Table 3, Figure 4). RAMP1
in HEK 293S cells also gave a small increase in potency for VIP
at stimulating this increase (Table 3, Figure 4A). RAMP3 had
no effect on coupling to Gi/o/t/z in either cell line. There was no
evidence of coupling of the VPAC2 to either Gq/11 or G12/13 in
HEK 293S cells in the absence or presence of any of the three
RAMPs (Supporting Information Figure S7).
RAMP2 had no effect on coupling of the CRF1 to Gs in the
presence of CRF. However, there was an enhanced coupling
to Gi/o/t/z, Gq/11 and G12/13 (Table 4, Figure 5). The differences
depended on the G-protein. For Gi/o/t/z (Figure 5B), there was
an enhancement of basal GTPgS binding and an increase in
CRF-stimulated maximum response. For Gq/11, the main effect
was an increase in the size of the CRF-stimulated maximum
response (Figure 5B). For G12/13, the main effect was to
increase the potency of CRF (Figure 5D). A very similar
pattern was seen for urocortin (Figure 5E–H, Table 4).
As RAMP2 increases CRF1 expression at the cell surface,
there was a possibility that the enhanced GTPgS binding
could be secondary to an increase in receptor number. Ini-
tially, the RAMP to receptor ratio was varied. If, instead of
transfecting each well with 1 mg of plasmid containing DNA
for the CRF1, 0.6 mg was used, receptor expression was virtu-
ally reduced back to control values in the absence of RAMP2
(112  6% of the expression of CRF1 seen in the absence of
RAMP2 measured by ELISA). The lower CRF1 expression made
little difference to the enhanced coupling seen to Gi/o/t/z in the
presence of RAMP2 (Supporting Information Figure S8).
Enhanced Ca2+ elevation for CRF1/RAMP2
The increased coupling seen to Gq/11 and Gi/o/t/z suggested
that RAMP2 should enhance CRF1-mediated intracellular
calcium mobilization. In HEK 293S cells there was a small
elevation of intracellular Ca2+ in response to agonists in
untransfected cells, suggesting low-level expression of an
endogenous CRF receptor. However, the response became
substantially larger following transfection with the CRF1 and
agonist potency also increased (Figure 6, Supporting Informa-
tion Table S1). Transfection with RAMP2 enhanced the
Table 2
Cell surface expression of receptors in the presence or absence of RAMPs
Receptor
HEK 293S CHO-K1
pcDNA3 RAMP1 RAMP2 RAMP3 pcDNA3 RAMP1 RAMP2 RAMP3
CTR 100 104  8 106  7 108  6 100 98  5 107  8 104  9
VPAC2 100 105  5 92  3 83  6 100 102  6 95  9 100  6
GLP-1R 100 103  4 98  3 81  5 100 101  5 92  7 79  9
CRF1 100 94  6 208  16* 97  7 100 95  5 125  7* 99  11
Receptors were detected by cell surface ELISA of their HA tag. Expression was normalized (100%) to that seen in the absence of any RAMP
[determined by cotransfecting with the appropriate receptor and empty vector (pcDNA3)]. Values are means  SEM, n > 3.
*Expression significantly different from pcDNA3, P < 0.05, Mann–Whitney.
Table 3
Chief effects of RAMPs on the coupling of the VPAC2 receptor to G-proteins
G-protein Cells RAMP pEC50 Emax Basal
Gi/o/t/z HEK293S No RAMP 6.79  0.06 102.7  2.8 1.3  1.6
Gi/o/t/z HEK293S RAMP 1 7.37  0.12* 106.6  3.8 27.9  2.7**
Gi/o/t/z HEK293S RAMP 2 7.45  0.13* 123.0  4.7 15.6  3.7*
Gi/o/t/z CHO-K1 No RAMP 7.01  0.16 104.2  4.2 -1.2  2.8
Gi/o/t/z CHO-K1 RAMP 1 7.29  0.09 110.3  2.9 21.7  2.1**
Gi/o/t/z CHO-K1 RAMP 2 7.05  0.16 108.6  6.1 17.9  4.0**
Values are means  SEM, n > 3.
*,**, P > 0.05, 0.01 or 0.001, relative to the parameter measured in the absence of a RAMP in the same cell line. Values compared using
Dunnett’s test following one-way ANOVA.
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Figure 1
Effects of RAMP co-transfection on the pharmacology of the VPAC2 expressed in HEK 293S (A–D) and CHO-K1 cells (E–H). Cells were transiently
transfected with either VPAC2 + pcDNA3, VPAC2 + RAMP1, VPAC2 + RAMP2, VPAC2 + RAMP3 or pcDNA3 alone. Values are normalized to the
maximum response to forskolin when applied to the receptor alone. Values are means  SEM, n > 3.
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maximum response seen to CRF by 81  2% and to urocortin
by 64  2% but had no effect on the response to sauvagine.
The mechanism responsible for the enhanced Ca2+ eleva-
tion was investigated by use of inhibitors (Table 5). In the
absence of RAMP2, the elevated intracellular calcium
appeared to be come entirely from an intracellular pool. Its
release was blocked by the PLC inhibitor U73122, and the
pool could be depleted by the CaATPase inhibitor thapsi-
gargin. By contrast, in the presence of RAMP2, there was
evidence for the use of extracellular Ca2+ in addition to this
intracellular pool. Removal of extracellular Ca2+ reduced the
response by about a one-third, and correspondingly, U73122
and thapsigargin only blocked about 2/3rd of the Ca2+ eleva-
tion. Pertussis toxin also inhibited the Ca2+ elevation by
around a one-third. As its effects were additive with those of
U73122 and thapsigargin but not with removal of extracel-
Figure 2
Effects of RAMP co-transfection on the pharmacology of the CRF1
expressed in HEK 293S cells. Cells were transiently transfected with
either CRF1 + pcDNA3, CRF1 + RAMP1, CRF1 + RAMP2, CRF1 + RAMP3
or pcDNA3 alone. Values are normalized to the maximum response
to forksolin when applied to the receptor alone. Values are means 
SEM, n > 3.
Figure 3
VIP-stimulated GTPgS binding to Gas in (a) HEK 293S and (b)
CHO-K1 cells following transient transfection of either VPAC2 +
pcDNA3, VPAC2 + RAMP1, VPAC2 + RAMP2 or VPAC2 + RAMP3.
Values are means  SEM, n > 3.
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lular Ca2+, it appears that the additional pool of extracellular
Ca2+ is utilized via a Gi/o/t/z-mediated pathway.
CRF function in Ramp2+/– mice
To further investigate whether there might be any physiologi-
cal consequences of CRF1/RAMP2 interactions, the ability of
CRF to increase plasma levels of ACTH was compared in
normal and Ramp2+/– mice (Kadmiel et al., 2011). Two hours
after CRF administration, the plasma ACTH concentration in
the Ramp2+/– animals was significantly reduced to levels that
were roughly 20% lower than similarly treated wild-type
control animals (Figure 7).
Discussion and conclusions
This study has demonstrated the coupling of two family B
GPCRs to RAMPs additional to those previously known. The
VPAC2 can interact with all three RAMPs; for RAMPs 1 and 2,
this leads to enhanced coupling to Gi/o/t/z. The CRF1 interacts
with RAMP2 leading to enhanced CRF1 expression at the cell
surface and increased coupling to Gi/o/t/z, Gq/11 and G12/13. The
Gi/o/t/z coupling results in extracellular Ca2+ entry following
challenge with CRF. RAMP2 association also reveals differ-
ences in the ability of CFR and urocortin on the one hand
and sauvagine on the other to increase intracellular calcium.
This study provides further evidence of the importance of
the cell line background in modulating the effects of RAMPs.
In the current study, the responses resulting from RAMP
interactions were consistently larger using HEK 293S com-
pared with CHO-K1 cells. In addition, a previous study inves-
tigating RAMP interactions revealed no association with the
VPAC2 (Christopoulos et al., 2003). Thus, care is needed in
interpreting negative data when investigating RAMP effects.
However, it is striking that the failure of the GLP1 receptor to
associate with any RAMP has now been observed in three cell
lines, consistently supporting the conclusion that it has very
little, if any, ability to associate with these proteins.
The diversity of RAMP effects are clearly illustrated in this
study. Only for CRF1 was there an effect on cell surface expres-
sion. A more general effect was to promote differential
G-protein coupling. This has previously been observed, for
the VPAC1 and the CTR (Christopoulos et al., 2003; Morfis
et al., 2008). In the case of the CTR, RAMP2 enhanced Gs
association whereas RAMP3 enhanced both Gs and Gq
(Morfis et al., 2008). In the current study, it appears that the
mechanism of enhancement depends on the individual
RAMP and the G-protein. Enhanced coupling of Gi/o/t/z was
observed to both the VPAC2 and the CRF1, and in all cases, the
main effect was an increase in basal G-protein activation. This
implies that the RAMP enhances baseline activity of both
receptors. With RAMP2, for both receptors when expressed in
HEK 293S cells, there was also an increase in the maximum
response, implying a greater number of active receptor–
Gi complexes; this mirrors the effect noted for the
VPAC1 : RAMP2 complex on enhanced phosphoinositide
breakdown (Christopoulos et al., 2003). The simplest inter-
pretation is that by some mechanism, the RAMP increases the
accessibility of the receptor to the G-protein (Morfis et al.,
2003). This effect was cell line-dependent as it was not seen in
the CHO-K1 cells. RAMP2 also enhanced coupling between
the CRF1 and Gq/11 and G12/13, but the mechanisms appeared to
be different. For Gq/11, the maximum response was increased,
suggesting an increased number of receptor–Gq/11 complexes.
For G12/13, the main effect was an increase in potency of both
CRF and a second agonist, urocortin 1. This implies an
increased affinity for the G-protein. A small increase in
potency for VIP was noted with Gi/o/t/z in HEK 293S cells,
although as there was also an increase in maximum response,
this might in part at least be due to increased accessibility of
the G-protein to the receptor. Regardless of this, it appears
that there are multiple mechanisms by which RAMPs can
modulate G-protein coupling.
The RAMP effects also depend on the nature of the
agonist. With CRF1, the calcium response to CRF and urocor-
tin 1 was enhanced whereas this was not observed with
sauvagine. Differential enhancement of agonist potency has
been observed at amylin receptors, where RAMP1 association
selectively increases the potency of CGRP at stimulating AC
Figure 4
VIP-stimulated GTPgS binding to Gai/o/t/z in (a) HEK 293S and (b)
CHO-K1 cells following transient transfection of either VPAC2 +
pcDNA3, VPAC2 + RAMP1, VPAC2 + RAMP2 or VPAC2 + RAMP3.Values
are means  SEM, n > 3.
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(Udawela et al., 2006b). It has been established that distinct
conformations of the CRF1 are involved in coupling to Gs and
Gi (Berger et al., 2006) and bias in agonist-signalling has been
observed at the CRF1 (Ruhmann et al., 1999; Grammatopou-
los et al., 2000; Beyermann et al., 2007; Grammatopoulos,
2012). Thus, in HEK 293S cells, sauvagine and urocortin are
equipotent at promoting GTPgS binding to Gs but urocortin
is more potent on Gi/o/t/z. Furthermore, it is possible to
discriminate between urocortin- and sauvagine-mediated
increases in GTPgS binding using antagonists (Berger et al.,
2006). Thus there is good evidence that the two agonists
promote different conformations of the CRF1, and this could
explain the different Ca2+ responses revealed after RAMP2
transfection.
The interactions between the VPAC2 and CRF1 and the
different RAMPs are potentially of physiological importance.
In the case of the CRF1 receptor, this study has shown that
the alterations in G-protein coupling cause changes in the
pattern of calcium mobilization in transfected cells and that
in mice, a genetic reduction in RAMP2 reduces the ability of
CRF to stimulate ACTH release. The ability of the CRF1 to
increase intracellular calcium (and especially the role of extra-
cellular calcium in that process) is known to be cell-type-
dependent (Soares et al., 2005; Gutknecht et al., 2008); the
presence of RAMP2 may be one factor behind this. CRF
stimulation of ACTH release is of pivotal importance to the
role of this hormone (Bale and Vale, 2004). The mechanism
by which RAMP2 modulates this response remains to be
established as this effect is normally considered to be medi-
ated via cAMP (Reisine et al., 1985), and no effect was
observed on this second messenger in the current study. As
the effects of RAMPs are cell-line-dependent, this may be less
of a paradox then first appears. Whatever the explanation,
the observation of reduced CRF responsiveness is consistent
with the RAMP2–CRF1 interaction being relevant in vivo.
Given that the animals are only heterozygote for RAMP2,
the reduction seen in ACTH levels may underestimate the
real contribution of RAMP2 association to enhancing the
response to CRF.
Comparison of the distribution of the VPAC2 and CRF1
receptors and the relevant RAMPs show there is potential for
co-expression in vivo. For CRF1 mRNA, there is overlap with
the reported distribution of RAMP2 mRNA in several rat brain
structures including the dentate gyrus, the CA1 and 3 regions
of the hippocampus, various regions of the amygdala, some
cortical layers and the dorsomedial hypothalamus (Potter
et al., 1994; Oliver et al., 2001). There is also reported to be
co-expression of mRNA and/or protein in human adipocytes
(Seres et al., 2004; Silaghi et al., 2007) and cerebral arteries,
albeit based on a rat-human comparison (Oliver et al., 2002;
Table 4
Effects of RAMP 2 on the coupling of the CRF1 receptor to G-proteins
Agonist G-protein
pEC50 Emax Basal pEC50 Emax Basal
No RAMP RAMP 2
CRF Gs 7.28  0.13 98.1  5.0 6.1  5.0 7.12  0.15 92.0  4.3 9.5  6.3
Urocotin Gs 7.56  0.16 109.9  6.4 -8.2  5.3 7.45  0.14 113.7  5.9 -9.8  4.7
CRF Gi/o/t/z 6.97  0.08 98.8  4.7 3.8  2.7 7.29  0.31 269.1  26.2** 65.3  17.6*
Urocortin Gi/o/t/z 7.25  0.16 96.4  5.7 -0.6  4.1 7.41  0.14 288.1  10.7*** 67.0  8.3***
CRF Gq 7.48  0.90 82.5  27.4 4.2  21.8 7.56  0.26 270.4  28.2** -3.7  22.4
Urocortin Gq 6.99  0.35 105.2  14.5 5.9  9.4 7.23  0.13 291.3  12.4*** 38.7  8.8
CRF G12 5.93  0.19 107.4  16.4 6.40  3.2 7.57  0.24** 138.4  12.8 -3.4  9.4
Urocortin G12 6.24  0.29 105.6  15.0 6.1  3.1 7.57  0.14* 176.4  7.3* 17.6  6.1
Values are means  SEM, n > 3. *,**,***P > 0.05, 0.01 or 0.001, relative to the parameter measured in the absence of RAMP 2 in the same
cell line. Values compared using by Student’s t-test.
Table 5
Inhibition of Ca2+ mobilization in response to activation of the CRF1
Inhibitors
% Inhibition of Ca2+
response following
stimulation by 1 mM CRF
CRF1 CRF1 + RAMP 2
None 0 0
+ U73122 99  2* 76  3*
+ Thapsigargin 98  3* 72  4*
+ PTx 12  8 32  7*
+PTx + U73122 100  4 100  1*
+ CTx 9  5 6  3
– Ca2+ 0  5 31  8*
– Ca2+ + U73122 100  1* 100  1*
– Ca2+ + Thapsigargin 100  1* 99  4*
– Ca2+ + PTx 9  2 41  5*
Intracellular calcium was measured as described in Methods.
Values are means  SEM, n > 3.
*Inhibition significantly different from 0%, P < 0.05, Mann–
Whitney.
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Figure 5
CRF- (a-d) and urocortin- (e-h) stimulated GTPgS binding to (A and E) Gas, (B and F) Gai, (C and G) Gaq and (D and H) Ga12 in HEK 293S cells
following transfection with CRF1+ pcDNA3 and CRF1 + RAMP2. Values are means  SEM of n = 3.
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Deussing et al., 2007). For the VPAC2, there are overlapping
distributions of the receptor with RAMPs 1 and 2 in similar
regions of rat brain to the CRF (Joo et al., 2004). In the
periphery, there are common distribution patterns in many
types of smooth muscle, especially vascular smooth muscle
(Knutsson and Edvinsson, 2002). These studies are no more
than suggestive; ultimately it will be necessary to show
co-localization of the relevant components in the same cells.
However, the current data suggest further work in this area
would be useful.
In conclusion, this work demonstrates the interaction of
RAMPs with two additional GPCRs. It suggests that RAMPs
can enhance G-protein interactions. These interactions can
have measurable consequences for cell signalling and for CRF
in vivo responsiveness.
Acknowledgements
We would like to thank AZ for financial support, Britt-Marie
Kihlberg for experimental assistance and Drs Dave Smith and
John Simms for scientific discussions. Portions of this study





Bale TL, Vale WW (2004). CRF and CRF receptors: role in stress
responsivity and other behaviors. Annu Rev Pharmacol Toxicol 44:
525–557.
Figure 6
Effect of RAMP2 on (a) CRF-induced, (b) Urocortin1-induced and (c)
sauvagine-induced Ca2+ mobilization in HEK 293S cells transfected
with either CRF1 + pcDNA3, CRF1 + RAMP2 or pcDNA3 alone. Values
are normalized to the maximum response produced by ATP. Values

























n = 8 n = 6
Wild-type Ramp2+/–
Figure 7
ACTH response to CRF in wild-type and Ramp2+/- mice. Male mice
were injected with 40 mg kg-1 CRF and plasma was collected 2 h
later. Plasma ACTH levels were measured by chemiluminescence
ELISA. Wild-type ACTH 156  47 pg mL-1; Ramp2+/- ACTH 124 
22 pg mL-1. Error bars represent SEM, n = 6–8. Values were com-
pared by Student’s t-test.
BJP D Wootten et al.
832 British Journal of Pharmacology (2013) 168 822–834
Berger H, Heinrich N, Wietfeld D, Bienert M, Beyermann M (2006).
Evidence that corticotropin-releasing factor receptor type 1 couples
to Gs- and Gi-proteins through different conformations of its
J-domain. Br J Pharmacol 149: 942–947.
Beyermann M, Heinrich N, Fechner K, Furkert J, Zhang W,
Kraetke O et al. (2007). Achieving signalling selectivity of ligands
for the corticotropin-releasing factor type 1 receptor by modifying
the agonist’s signalling domain. Br J Pharmacol 151: 851–859.
Bomberger JM, Spielman WS, Hall CS, Weinman EJ,
Parameswaran N (2005). Receptor activity-modifying protein
(RAMP) isoform-specific regulation of adrenomedullin receptor
trafficking by NHERF-1. J Biol Chem 280: 23926–23935.
Bouschet T, Martin S, Henley JM (2005).
Receptor-activity-modifying proteins are required for forward
trafficking of the calcium-sensing receptor to the plasma
membrane. J Cell Sci 118 (Pt 20): 4709–4720.
Christopoulos A, Christopoulos G, Morfis M, Udawela M,
Laburthe M, Couvineau A et al. (2003). Novel receptor partners and
function of receptor activity-modifying proteins. J Biol Chem 278:
3293–3297.
Conner AC, Hay DL, Simms J, Howitt SG, Schindler M, Smith DM
et al. (2005). A key role for transmembrane prolines in calcitonin
receptor-like receptor agonist binding and signalling: implications
for family B G-protein-coupled receptors. Mol Pharmacol 67: 20–31.
Dackor R, Fritz-Six K, Smithies O, Caron K (2007). Receptor
activity-modifying proteins 2 and 3 have distinct physiological
functions from embryogenesis to old age. J Biol Chem 282:
18094–18099.
Dautzenberg FM, Py-Lang G, Higelin J, Fischer C, Wright MB,
Huber G (2001). Different binding modes of amphibian and human
corticotropin-releasing factor type 1 and type 2 receptors: evidence
for evolutionary differences. J Pharmacol Exp Ther 296: 113–120.
Deussing JM, Kuhne C, Putz B, Panhuysen M, Breu J,
Stenzel-Poore MP et al. (2007). Expression profiling identifies the
CRH/CRH-R1 system as a modulator of neurovascular gene activity.
J Cereb Blood Flow Metab 27: 1476–1495.
Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB (2003). The
G-protein-coupled receptors in the human genome form five main
families. Phylogenetic analysis, paralogon groups, and fingerprints.
Mol Pharmacol 63: 1256–1272.
Grammatopoulos DK (2012). Insights into mechanisms of
corticotropin-releasing hormone receptor signal transduction.
Br J Pharmacol 166: 85–97.
Grammatopoulos DK, Randeva HS, Levine MA, Katsanou ES,
Hillhouse EW (2000). Urocortin, but not corticotropin-releasing
hormone (CRH), activates the mitogen-activated protein kinase
signal transduction pathway in human pregnant myometrium: an
effect mediated via R1alpha and R2beta CRH receptor subtypes and
stimulation of Gq-proteins. Mol Endocrinol 14: 2076–2091.
Gutknecht E, Van der Linden I, Van Kolen K, Verhoeven KF,
Vauquelin G, Dautzenberg FM (2008). Molecular mechanisms of
corticotropin releasing factor receptor-induced calcium signaling.
Mol Pharmacol 75: 648–657.
Hay DL, Poyner DR, Sexton PM (2006). GPCR modulation by
RAMPs. Pharmacol Ther 109: 173–197.
Hong Y, Hay DL, Quirion R, Poyner DR (2011). The pharmacology
of Adrenomedullin 2/Intermedin. Br J Pharmacol 166: 110–120.
Joo KM, Chung YH, Kim MK, Nam RH, Lee BL, Lee KH et al. (2004).
Distribution of vasoactive intestinal peptide and pituitary adenylate
cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1
receptor) in the rat brain. J Comp Neurol 476: 388–413.
Kadmiel M, Fritz-Six K, Pacharne S, Richards GO, Li M, Skerry TM
et al. (2011). Research resource: haploinsufficiency of receptor
activity-modifying protein-2 (RAMP2) causes reduced fertility,
hyperprolactinemia, skeletal abnormalities, and endocrine
dysfunction in mice. Mol Endocrinol 25: 1244–1253.
Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010).
NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160:
1577–1579.
Knutsson M, Edvinsson L (2002). Distribution of mRNA for VIP and
PACAP receptors in human cerebral arteries and cranial ganglia.
Neuroreport 13: 507–509.
McGrath J, Drummond G, Kilkenny C, Wainwright C (2010).
Guidelines for reportingexperiments involving animals: the ARRIVE
guidelines. Br J Pharmacol 160: 1573–1576.
McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N
et al. (1998). RAMPs regulate the transport and ligand specificity of
the calcitonin-receptor-like receptor. Nature 393: 333–339.
Morfis M, Christopoulos A, Sexton PM (2003). RAMPs: 5 years on,
where to now? Trends Pharmacol Sci 24: 596–601.
Morfis M, Tilakaratne N, Furness SG, Christopoulos G, Werry TD,
Christopoulos A et al. (2008). Receptor activity-modifying proteins
differentially modulate the G protein-coupling efficiency of amylin
receptors. Endocrinology 149: 5423–5431.
Oliver KR, Kane SA, Salvatore CA, Mallee JJ, Kinsey AM, Koblan KS
et al. (2001). Cloning, characterization and central nervous system
distribution of receptor activity modifying proteins in the rat. Eur J
Neurosci 14: 618–628.
Oliver KR, Wainwright A, Edvinsson L, Pickard JD, Hill RG (2002).
Immunohistochemical localization of calcitonin receptor-like
receptor and receptor activity-modifying proteins in the human
cerebral vasculature. J Cereb Blood Flow Metab 22: 620–629.
Potter E, Sutton S, Donaldson C, Chen R, Perrin M, Lewis K et al.
(1994). Distribution of corticotropin-releasing factor receptor mRNA
expression in the rat brain and pituitary. Proc Natl Acad Sci USA
91: 8777–8781.
Poyner DR, Andrew DP, Brown D, Bose C, Hanley MR (1992).
Pharmacological characterization of a receptor for calcitonin
gene-related peptide on rat, L6 myocytes. Br J Pharmacol 105:
441–447.
Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W
et al. (2002). International Union of Pharmacology. XXXII. The
mammalian calcitonin gene-related peptides, adrenomedullin,
amylin, and calcitonin receptors. Pharmacol Rev 54:
233–246.
Reisine T, Rougon G, Barbet J, Affolter HU (1985).
Corticotropin-releasing factor-induced adrenocorticotropin
hormone release and synthesis is blocked by incorporation of the
inhibitor of cyclic AMP-dependent protein kinase into anterior
pituitary tumor cells by liposomes. Proc Natl Acad Sci USA 82:
8261–8265.
Ruhmann A, Bonk I, Kopke AK (1999). High-affinity binding of
urocortin and astressin but not CRF to G protein-uncoupled CRFR1.
Peptides 20: 1311–1319.
Seres J, Bornstein SR, Seres P, Willenberg HS, Schulte KM,
Scherbaum WA et al. (2004). Corticotropin-releasing hormone
system in human adipose tissue. J Clin Endocrinol Metab 89:
965–970.
BJPRAMP interactions with VPAC2 and CRF1 receptors
British Journal of Pharmacology (2013) 168 822–834 833
Silaghi A, Achard V, Paulmyer-Lacroix O, Scridon T, Tassistro V,
Duncea I et al. (2007). Expression of adrenomedullin in human
epicardial adipose tissue: role of coronary status. Am J Physiol
Endocrinol Metab 293: E1443–E1450.
Soares SM, Thompson M, Chini EN (2005). Role of the
second-messenger cyclic-adenosine 5’-diphosphate-ribose on
adrenocorticotropin secretion from pituitary cells. Endocrinology
146: 2186–2192.
Tilakaratne N, Christopoulos G, Zumpe ET, Foord SM, Sexton PM
(2000). Amylin receptor phenotypes derived from human
calcitonin receptor/RAMP coexpression exhibit pharmacological
differences dependent on receptor isoform and host cell
environment. J Pharmacol Exp Ther 294: 61–72.
Tsutsumi M, Claus TH, Liang Y, Li Y, Yang L, Zhu J et al. (2002).
A potent and highly selective VPAC2 agonist enhances
glucose-induced insulin release and glucose disposal: a potential
therapy for type 2 diabetes. Diabetes 51: 1453–1460.
Udawela M, Christopoulos G, Morfis M, Christopoulos A, Ye S,
Tilakaratne N et al. (2006a). A critical role for the short intracellular
C terminus in receptor activity-modifying protein function. Mol
Pharmacol 70: 1750–1760.
Udawela M, Christopoulos G, Tilakaratne N, Christopoulos A,
Albiston A, Sexton PM (2006b). Distinct receptor activity-modifying
protein domains differentially modulate interaction with calcitonin
receptors. Mol Pharmacol 69: 1984–1989.
Wootten DL, Simms J, Hay DL, Christopoulos A, Sexton PM (2010).
Receptor activity modifying proteins and their potential as drug
targets. Prog Mol Biol Transl Sci 91: 53–79.
Supporting information
Additional Supporting Information may be found in the
online version of this article:
Figure S1 Failure of HEK 293 cells transfected with CLR
alone to respond to CGRP or adrenomedullin (ADM). Values
are means  range of duplicate determinations from a single
experiment.
Figure S2 Failure of CHO-K1 cells transfected with CLR
alone to respond to CGRP or ADM. Values are means  range
of duplicate determinations from a single experiment.
Figure S3 Effects of epitope tags on the VPAC2, GLP-1, CRF1
and CT receptors transiently expressed in CHO-K1 cells.
Values are means  SD, n = 2.
Figure S4 Effects of epitope tags on the pharmacology of
CGRP, AM1 or AM2 receptors expressed in HEK-293 cells.
Number indicates the residue in the RAMP to which the FLAG
tag was attached. Values are means  SEM from three inde-
pendent experiments experiment.
Figure S5 Pharmacology of VPAC2 receptor transfected with
RAMPs in CHO-K1 cells. Values are means  SEM from three
independent experiments.
Figure S6 Pharmacology of CRF1 receptor transfected with
RAMP2 in CHO-K1 cells. Values are means  SEM determined
from three independent experiments performed in duplicate.
Figure S7 GTPgS stimulation mediated by the VPAC2 in the
presence or absence of RAMPs in HEK293 cells. Top; stimula-
tion of binding to G12/13. Bottom, stimulation of binding to
Gq/G11. A small signal was detected but this was also observed
in a RAMP1 only transfection. Experiments are representative
of three. Values are means  SEM of three independent
experiments performed in duplicate.
Figure S8 Effects of varying CRF1R cDNA concentration on
CRF-stimulated GTPgS to Gi in HEK 293S cells. Values are
normalized to the maximum response seen in cells trans-
fected with CRF1R alone. Values are means  SEM of three
independent experiments performed in duplicate.
Table S1 Effects of RAMP2 on the CRF1-mediated elevation
in intracellular calcium in HEK 293S cells.
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